Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals’ Ziihera poised to reshape HER2‑positive gastro‑oncology with late‑breaking ASCO GI data, offering new survival benefits and growth prospects.

Jazz Pharmaceuticals reported a net loss of $718.47 million in Q2 2025, despite a 13% year-over-year revenue growth in its narcolepsy treatment Xywav, and announced a leadership transition with Renee Gala as the new President and CEO.

Jazz Pharmaceuticals PLC has announced its second quarter 2025 financial results, alongside a leadership transition with Renee Gala taking over as President and CEO, promising to drive sustained growth and innovation in the biopharmaceutical industr…

Jazz Pharmaceuticals PLC continues to navigate the evolving biopharmaceutical landscape with a strategic focus on innovation and patient care, positioning itself for emerging opportunities in oncology and other therapeutic areas.

Jazz Pharmaceuticals PLC has made significant strides in both the US and international markets, with notable growth highlights and a major expansion into China through the approval of its JAZZ range by the CFDA.

Jazz Pharmaceuticals reported Q1 2025 revenues of $898 million, driven by growth in key products, but fell short of earnings estimates, sparking discussions about its valuation and future prospects.